Association of ACR50 response with mean changes from baseline to Week 104 in patient-reported outcome scores.
| ACR50 Improvement Status, adjusted mean (SE) for change scores | |||
|---|---|---|---|
| Measure | Nonresponder, n = 169 | ACR50 Responder, n = 369 | Overall p† |
| HAQ-DI | –0.6 (0.04) | –1.2 (0.03) | < 0.0001 |
| SF-36 PCS | 7.2 (0.65) | 17.4 (0.45) | < 0.0001 |
| SF-36 MCS | 4.7 (0.81) | 8.8 (0.56) | < 0.0001 |
| SF-6D | 0.10 (0.01) | 0.22 (0.01) | < 0.0001 |
| FACIT-F | 8.1 (0.69) | 15.9 (0.47) | < 0.0001 |
| HUI-3 | 0.22 (0.02) | 0.41 (0.01) | < 0.0001 |
↵† p for overall test of differences between ACR50 responder groups from an analysis of covariance model that included ACR50 responder group, baseline score, age, and, sex. ACR50: American College of Rheumatology rating scale (50% or more improvement); FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI: Health Assessment Questionnaire Disability Index; HUI-3: Health Utility Index Mark 3: MCS: mental component summary; PCS: physical component summary; SF-6D: Short-Form 6 Dimension; SF-36: Short-Form 36 Health Survey.